×
0 0 0 0 0 0 0 0
Stockreport

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

GALAPAGOS NV ADS (GLPG)  More Company Research Source: GlobeNewswire
Last galapagos nv ads earnings: 4/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: glpg.com/company-overview
PDF Evaluation of C1 corrector GLPG2222 on top of ivacaftor (Kalydeco®[1]) in heterozygous Class III/F508del CFTR patients Patient study recruited within 5 months in Europe and Australia GLPG2222 was well tolerated dosed once daily for 28 days Dose dependent increase in FEV1 Statistically significant dose dependent decreases in sweat chloride Further clinical validation of in vitro predictive platform Mechelen, Belgium; 19 November 2017, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222. The ALBATROSS study included 37 cystic fibrosis patients with a gating (Class III) mutation on one allele and F508del (Class II) mutation on the other allele. All patients were on long-term stable Kalydeco treatment (150mg twice daily) at screening and continued their Kalydeco treatment throughout the study. The ALBATROSS study was fully recruited within five month [Read more]

IMPACT SNAPSHOT EVENT TIME: GLPG
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS